• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 3 - Provider Buy-in and Clinical Pathway Development

Article

Dr Yu said that it is crucial for providers' voices to be heard in pathway development.

Dr Yu said that it is crucial for providers’ voices to be heard in pathway development.

“If you’re going to be successful, you need to have buy-in. If you need to have buy-in, you need to have people believe that it’s a transparent process of pathways development that they respect and feel that they had a voice in,” he explained.

He detailed how a healthcare setting can also impact pathway development, and the role that published medical literature has on the real-world setting practice. The actual experience of implementing pathways and patient behavior need to be closely monitored. There should also be feedback loops that include physicians.

Dr Tischler agreed, saying that provider buy-in is necessary. He said that for authentic buy-in, one cannot force a caregiver to act or practice in a certain way.

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
Benjamin Scirica, MD, MPH, associate professor of medicine at Harvard Medical School and director of quality initiatives at Brigham and Women’s Hospital’s Cardiovascular Division
dr andrew leitner
Laurence Sperling, MD
Glenn Balasky during a video interview
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.